These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 21848793)

  • 21. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.
    Zitt E; Jäger C; Rosenkranz AR; Eigner M; Kodras K; Kovarik J; Graf H; Pétavy F; Horn S; Watschinger B
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):45-52. PubMed ID: 21253777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.
    Hemetsberger M; Oberbauer R; Erb H; Pronai W
    Wien Med Wochenschr; 2015 Oct; 165(19-20):410-8. PubMed ID: 26302869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.
    Spiegel DM; Casey L; Bell S; Parker M; Chonchol M
    Hemodial Int; 2006 Oct; 10 Suppl 2():S24-7. PubMed ID: 17022747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet].
    Segura Torres P; Borrego Utiel FJ; Sánchez Perales MC; García Cortés MJ; Biechy Baldán MM; Pérez Bañasco V
    Nefrologia; 2010; 30(4):443-51. PubMed ID: 20651886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
    Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term use of cinacalcet in children on regular hemodialysis.
    Youssef D
    Arab J Nephrol Transplant; 2012 Jan; 5(1):51-3. PubMed ID: 22283867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
    Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
    Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients.
    Al-Hilali N; Hussain N; Kawy YA; Al-Azmi M
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):448-55. PubMed ID: 21566299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice.
    Bover J; Perez R; Molina M; Benavides B; Ariza F; Miguel JL; Tornero F; Torregrosa JV;
    Nephron Clin Pract; 2011; 118(2):c109-21. PubMed ID: 21150219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
    Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
    Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.